Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + Obinutuzumab in B-Cell Malignancies
NCT02569476Phase 1Completed
- Sponsor
- BeiGene
- Start
- Jan 2016
- Primary completion
- Sep 2020
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of zanubrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL) and 4 more, sponsored by BeiGene. Primary endpoints: Number Of Participants Experiencing Adverse Events, Number Of Participants With Clinical Laboratory Abnormalities and 3 more. Started Jan 2016; status: completed.
02
Drugs
zanubrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT02569476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02569476.